Consequently, in the setting of diagnosing an early-stage, ER-positive, HER2-negative carcinoma in a male patient, this study provides provisional data supporting the use of the 21-gene expression assay to provide prognostication and predict benefit of prescribing chemoendocrine agents. This evidence concerns the gene ERBB2 and carcinoma.